Media Articles Related to Reminyl (Galantamine)
Study demonstrated clinically meaningful and statistically significant improvement of agitation in patients with Alzheimer's disease
Source: Anxiety / Stress News From Medical News Today [2014.10.16]
Avanir Pharmaceuticals, Inc. has announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014...
Laying siege to beta-amyloid, the key protein in Alzheimer's disease
Source: Huntingtons Disease News From Medical News Today [2014.10.06]
The peptide - a small protein - beta-amyloid is strongly associated with Alzheimer's disease; however, researchers are still looking for unequivocal proof that this peptide is the causal agent of the...
Memory and Alzheimer's disease
Source: Schizophrenia News From Medical News Today [2014.09.03]
Research by Dr. Sylvain Williams shows that the flow of activity in the hippocampus, a brain region essential for memory, is actually bidirectional, rather than just unidirectionalA study just...
Protein implicated in Alzheimer's disease has important treatment potential in genetic form of epilepsy
Source: Epilepsy News From Medical News Today [2014.08.16]
Researchers at the Gladstone Institutes have shown that reducing brain levels of the protein tau effectively blocks the development of disease in a mouse model of Dravet syndrome, a severe...
Source: MedicineNet First Aid Specialty [2014.08.05]
Title: Alzheimer's Disease
Category: Symptoms and Signs
Created: 8/5/2014 2:43:00 PM
Last Editorial Review: 8/5/2014 2:43:52 PM
Published Studies Related to Reminyl (Galantamine)
Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.
Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. 
Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment... Treatment was generally safe and well tolerated.
Galantamine improves sustained attention in chronic cocaine users. 
Chronic cocaine users are known to have cognitive deficits that are predictive of
poor treatment response. Whether these deficits improve with medications
targeting specific cognitive functions has not been examined in previous studies.
Clinical Trials Related to Reminyl (Galantamine)
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Active, not recruiting]
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat
problems with thinking and memory caused by electroconvulsive therapy (ECT).
A Study of the Safety and Effectiveness of Galantamine Hydrobromide (REMINYL«) in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to evaluate the safety and effectiveness of galantamine
hydrobromide (REMINYL«) in patients with Alzheimer's disease who have not received or have
not responded to treatment with medication similar to galantamine hydrobromide (REMINYL«).
Effects of Galantamine on Cognition [Recruiting]
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early
twenties, with cognitive impairments and negative symptoms frequently emerging much earlier.
Such cognitive impairments and negative symptoms but much milder are also observed in
high-risk groups (such as relatives of schizophrenia patients), who may or may not develop
the full blown psychotic disorder. Our study plans to recruit such non-ill subjects to test
the effects of galantamine on clinical/physiological/cognitive measures. This study serves
several goals: If a drug is found effective in treating subtle deficits, then it will
provide treatment strategy in individuals with schizophrenia spectrum personality disorders
and for early intervention in schizophrenia. In addition, one of the difficulties of
testing a drug on schizophrenia is that patients take other medications (i. e., antipsychotic
drugs) that can change the effects of the test drug. The proposed study will be in subjects
who will not be taking antipsychotic medications. Our study will be carried out in two
sessions, at least one month apart. Subjects will be randomly assigned to the two possible
order of administration: the drug and then placebo, or the placebo and then drug. Subjects
will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8
mg (or placebo) on the 4th day, the day of testing. We will administer a battery of
clinical/cognitive/neurophysiological tests after the 8 mg drug dose.
A Single Dose, Cross-Over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers [Completed]
The purpose of this open-label, single dose, two-treatment, two-period, cross-over study is
to evaluate the pharmacokinetic profile and tolerability of galantamine oral solution and
Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl´┐Ż) [Recruiting]
Alzheimer's disease (AD) is characterized by progressive subcortical and cortical neuronal
degeneration. AD patients differ in the time course of neuronal degeneration and
accompanying cognitive decline.
With recent advances in MR imaging, including optimized data acquisition and processing
techniques, tools that are especially well suited for tracking long-term pathological
changes as well as drug treatment effects have become available. In addition to structural
imaging, new acquisition and analysis techniques have been developed to determine integrity
of subcortical fiber tracts in vivo.
In the present project we propose to determine predictors of disease progression and
treatment response and investigate potential treatment effects on structural disease
progression, covering the continuum from axonal degeneration to cortical neuronal loss
taking advantage of recent advances in MRI acquisition and analysis techniques.